1. Home
  2. KSS vs NUVB Comparison

KSS vs NUVB Comparison

Compare KSS & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kohl's Corporation

KSS

Kohl's Corporation

HOLD

Current Price

$19.84

Market Cap

2.0B

ML Signal

HOLD

Logo Nuvation Bio Inc.

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$6.29

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSS
NUVB
Founded
1962
2018
Country
United States
United States
Employees
N/A
307
Industry
Department/Specialty Retail Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
KSS
NUVB
Price
$19.84
$6.29
Analyst Decision
Sell
Strong Buy
Analyst Count
15
8
Target Price
$15.31
$11.38
AVG Volume (30 Days)
2.9M
6.3M
Earning Date
05-28-2026
05-04-2026
Dividend Yield
3.58%
N/A
EPS Growth
142.86
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$203.82
Revenue Next Year
$0.21
$58.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.85
$2.18
52 Week High
$25.22
$9.75

Technical Indicators

Market Signals
Indicator
KSS
NUVB
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
KSS
NUVB

About KSS Kohl's Corporation

Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Share on Social Networks: